References
- Marcellino A, Lubrano R. Letter to the editor: type of proteinuria might be essential for RAAS-I treatment in children with CAKUT. Expert Rev Clin Pharmacol. 2023. https://www.tandfonline.com/doi/full/10.1080/17512433.2023.2295004?src=recsys
- Rivetti G, Gizzone P, Di Sessa A, et al. Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed. Expert Rev Clin Pharmacol. 2023;16(9):791–798. doi: 10.1080/17512433.2023.2247985
- Matsell DG, Catapang M. Predicting outcomes and improving care in children with congenital kidney anomalies. doi: 10.1007/s00467-020-04677-2/Published
- Stonebrook E, Hoff M, Spencer JD. Congenital anomalies of the kidney and urinary tract: a clinical review. Curr Treat Options Pediatr. 2019;5:223. doi: 10.1007/S40746-019-00166-3
- Tuttle KR. Albuminuria reduction: the holy grail for kidney protection holy grail: a distant, ultimate goal. Kidney Int. 2007;72(7):785–786. doi: 10.1038/sj.ki.5002505
- Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: managing potassium and renal function. Cleve Clin J Med. 2019;86(9):601–607. doi: 10.3949/CCJM.86A.18024
- KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;33:1–150.
- Narasimhan KL, Mahajan JK, Kaur B, et al. The vesicoureteral reflux dysplasia syndrome in patients with posterior urethral valves. J Urol. 2005;174(4 Part 1):1433–1435. doi: 10.1097/01.JU.0000173129.70381.E9
- Konda R, Kakizaki H, Nakai H, et al. Urinary concentrations of alpha-1-microglobulin and albumin in patients with reflux nephropathy before and after puberty. Nephron. 2002;92(4):812–816. doi: 10.1159/000065462
- Kohl S, Avni FE, Boor P, et al. Definition, diagnosis and clinical management of non-obstructive kidney dysplasia: a consensus statement by the ERKNet Working group on kidney malformations. doi: 10.1093/ndt/gfac207
- Simões Silva A C, Lanza K, Andrade Palmeira V, et al. 2020 update on the renin–angiotensin–aldosterone system in pediatric kidney disease and its interactions with coronavirus. Pediatr Nephrol. 2021;36(6):1407–1426. doi: 10.1007/s00467-020-04759-1/Published
- Mastrangelo A, Brambilla M, Romano G, et al. Single, double and triple blockade of RAAS in Alport syndrome: different tools to freeze the evolution of the disease. J Clin Med. 2021;10(21):4946. doi: 10.3390/JCM10214946
- Lubrano R, Soscia F, Elli M, et al. Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria. Pediatrics. 2006;118(3):e833–e838. doi: 10.1542/PEDS.2005-2053